Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance

• Published in: Medical oncology (Northwood, London, England) London, England), 2014, Vol.31 (1), p.810-810, Article 810
• Main Authors: Zhao, Ze-Rui, Wang, Jin-Feng, Lin, Yong-Bin, Wang, Fang, Fu, Sha, Zhang, Shu-Lin, Su, Xiao-Dong, Jiang, Long, Zhang, Yi-Gong, Shao, Jian-Yong, Long, Hao
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Hematology; Humans; Internal Medicine; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medicine; Medicine & Public Health; Middle Aged; Mutation; Neoplasm Metastasis; Oncology; Original Paper; Pathology; Proportional Hazards Models; Protein Kinase Inhibitors - administration & dosage; Protein-Tyrosine Kinases - antagonists & inhibitors; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; Regression Analysis; Retrospective Studies; Treatment Outcome
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-013-0810-6

There is no consensus in the salvage treatment for non-small-cell lung cancer (NSCLC) with acquired resistance to primary epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs). Fifty-one consecutive EGFR-mutated NSCLC patients with TKI retreatment after acquired resistance were enrolled in this study. The quantitation of mutation abundance was performed by real-time fluorescent quantitative PCR. The correlation between mutation abundance and outcomes of readministrated TKI was analyzed by survival analysis. Patients with high (H) mutation abundance (24/51) had a significantly (log-rank, P